A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma

Trial Identifier: ACT17453
Sponsor: Sanofi
Start Date: April 2023
Primary Completion Date: February 2026
Study Completion Date: May 2028
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales Wollongong, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria Fitzroy, Victoria, AUSTRALIA, 3065
BRAZIL, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, BRAZIL, 90110-270
BRAZIL, São Paulo Sao Paulo, São Paulo, BRAZIL, 05403-000
BRAZIL, São Paulo Sao Paulo, São Paulo, BRAZIL, 04537-081
CHINA Changsha, CHINA, 410013
CHINA Guangzhou, CHINA, 510060
CHINA Nanchang, CHINA, 330006
CHINA Shenyang, CHINA, 110022
CHINA Tianjin, CHINA, 300060
CHINA Tianjin, CHINA, 300020
CHINA Wuhan, CHINA, 430030
CZECHIA Brno, CZECHIA, 62500
CZECHIA Olomouc, CZECHIA, 77900
CZECHIA Ostrava - Poruba, CZECHIA, 70852
CZECHIA Praha 2, CZECHIA, 12808
GREECE Athens, GREECE, 11528
GREECE Athens, GREECE, 10676
JAPAN, Chiba Kashiwa-shi, Chiba, JAPAN, 277-8577
JAPAN, Okayama Okayama-shi, Okayama, JAPAN, 701-1192
PORTUGAL Braga, PORTUGAL, 4710-243
PORTUGAL Lisboa, PORTUGAL, 1400-038
PORTUGAL Lisboa, PORTUGAL, 1649-035